Jasper Therapeutics Files 8-K on Financials
Ticker: JSPRW · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1788028
| Field | Detail |
|---|---|
| Company | Jasper Therapeutics, Inc. (JSPRW) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $115.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: JSPR
TL;DR
Jasper Therapeutics dropped an 8-K on March 4th detailing their financial condition and results.
AI Summary
Jasper Therapeutics, Inc. filed an 8-K on March 4, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. Jasper Therapeutics, Inc. is a biotechnology company incorporated in Delaware.
Why It Matters
This filing provides crucial updates on Jasper Therapeutics' financial health and operational status, which is important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing providing financial updates and does not indicate any immediate or significant risks.
Key Players & Entities
- Jasper Therapeutics, Inc. (company) — Registrant
- March 4, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39138 (identifier) — SEC File Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 4, 2024.
What is the SEC file number for Jasper Therapeutics, Inc.?
The SEC file number for Jasper Therapeutics, Inc. is 001-39138.
In which state was Jasper Therapeutics, Inc. incorporated?
Jasper Therapeutics, Inc. was incorporated in Delaware.
What is the SIC code for Jasper Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Jasper Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-03-04 07:40:22
Key Financial Figures
- $0.0001 — stered Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Mar
- $115.00 — ng Common Stock at an exercise price of $115.00 JSPRW The Nasdaq Stock Market LLC
Filing Documents
- ea0201079-8k_jasper.htm (8-K) — 36KB
- ea0201079ex99-1_jasper.htm (EX-99.1) — 88KB
- ex99-1_001.jpg (GRAPHIC) — 22KB
- 0001213900-24-019249.txt ( ) — 382KB
- jspr-20240304.xsd (EX-101.SCH) — 4KB
- jspr-20240304_def.xml (EX-101.DEF) — 26KB
- jspr-20240304_lab.xml (EX-101.LAB) — 36KB
- jspr-20240304_pre.xml (EX-101.PRE) — 25KB
- ea0201079-8k_jasper_htm.xml (XML) — 6KB
02
Item 2.02. R esults of Operations and Financial Condition . On March 4, 2024, Jasper Therapeutics, Inc. issued a press release announcing results for the fiscal quarter and year ended December 31, 2023 and reporting recent corporate developments. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release, dated March 4, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. JASPER THERAPEUTICS, INC. Date: March 4, 2024 By: /s/ Herb Cross Name: Herb Cross Title: Chief Financial Officer 2